01:20 PM EDT, 05/14/2024 (MT Newswires) -- NeuroSense Therapeutics ( NRSN ) said Tuesday it has teamed up with PhaseV for clinical trial of PrimeC for treating amyotrophic lateral sclerosis, or ALS.

PhaseV's independent analysis of NeuroSense's PARADIGM phase 2b study, using causal machine learning, predicts a high success probability in multiple subgroups for the phase 3 trial, NeuroSense said. These findings will guide study design, patient enrollment, and cost-effectiveness measures, it added.

Financial details of the collaboration were not disclosed.

NeuroSense shares were up nearly 4% in recent trading.

Price: 1.16, Change: +0.04, Percent Change: +3.57